{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:16:18Z","timestamp":1788203778903,"version":"build-2803163510"},"reference-count":69,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Aortic stenosis (AS) is the most common valvular heart disease in ageing populations and is associated with substantial morbidity and mortality. Despite advances in surgical and transcatheter valve replacement, no medical therapy has yet been shown to prevent disease onset or slow progression. Calcific AS is now recognised as an active, multifactorial process involving lipid infiltration, inflammation and osteogenic calcification of the aortic valve. Lipoprotein(a) has emerged as a key contributor to these mechanisms and is a genetically determined, lifelong cardiovascular risk factor. Lipoprotein(a) is a major carrier of oxidised phospholipids, which promote valvular inflammation and calcification. Epidemiological and Mendelian randomisation studies consistently demonstrate a strong and likely causal association between elevated lipoprotein(a) and AS. Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops. The recent development of lipoprotein(a)-lowering therapies has renewed interest in targeting this pathway, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in clinical trials.<\/jats:p>","DOI":"10.15420\/ecr.2025.101","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:16:28Z","timestamp":1787681788000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-3339","authenticated-orcid":false,"given":"Lale","family":"Tokgozoglu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04kwvgz42","id-type":"ROR","asserted-by":"publisher"}],"name":"Hacettepe University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-5227","authenticated-orcid":false,"given":"Meral","family":"Kayikcioglu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02eaafc18","id-type":"ROR","asserted-by":"publisher"}],"name":"Ege University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Aluru JS, Barsouk A, Saginala K, et al. Valvular heart disease epidemiology. Med Sci (Basel) 2022;10:32. https:\/\/doi.org\/10.3390\/medsci10020032; PMID: 35736352. DOI: 10.3390\/medsci10020032","DOI":"10.3390\/medsci10020032"},{"key":"ref1","unstructured":"Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013;62:1002\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.015; PMID: 23727214."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kearney LG, Ord M, Buxton BF, et al. Progression of aortic stenosis in elderly patients over long-term follow up. Int J Cardiol 2013;167:1226\u201331. https:\/\/doi.org\/10.1016\/j.ijcard.2012.03.139; PMID: 22483251. DOI: 10.1016\/j.ijcard.2012.03.139","DOI":"10.1016\/j.ijcard.2012.03.139"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Stewart S, Afoakwah C, Chan YK, et al. Counting the cost of premature mortality with progressively worse aortic stenosis in Australia: a clinical cohort study. Lancet Healthy Longev 2022;3:e599\u2013606. https:\/\/doi.org\/10.1016\/S2666-7568(22)00168-4; PMID: 36102774. DOI: 10.1016\/S2666-7568(22)00168-4","DOI":"10.1016\/S2666-7568(22)00168-4"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kim AR, Ahn JM, Kang DY, et al. Association of lipoprotein(a) with severe degenerative aortic valve stenosis. JACC Asia 2024;4:751\u201360. https:\/\/doi.org\/10.1016\/j.jacasi.2024.07.007; PMID: 39553905. DOI: 10.1016\/j.jacasi.2024.07.007","DOI":"10.1016\/j.jacasi.2024.07.007"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kayikcioglu M, Ozkan HS, Tokgozoglu L. Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Eur Atheroscler J 2022;1:54\u201368. https:\/\/doi.org\/10.56095\/eaj.v1i3.21. DOI: 10.56095\/eaj.v1i3.21","DOI":"10.56095\/eaj.v1i3.21"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361; PMID: 36036785. DOI: 10.1093\/eurheartj\/ehac361","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Myasoedova VA, Valerio V, Rusconi V, et al. Systemic inflammation and fibrocalcific remodeling in aortic stenosis: the interplay of lipoprotein(a), sex, and valve morphology. J Transl Med 2025;23:1070. https:\/\/doi.org\/10.1186\/s12967-025-07061-6; PMID: 41063250. DOI: 10.1186\/s12967-025-07061-6","DOI":"10.1186\/s12967-025-07061-6"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Koschinsky ML, Kalra DK, Boffa MB. Lipoprotein(a): an underappreciated inherited risk factor for atherosclerosis, aortic stenosis, and abdominal aortic aneurysm. Annu Rev Med 2025;77:31\u201343. https:\/\/doi.org\/10.1146\/annurev-med-050124-025051; PMID: 41232565. DOI: 10.1146\/annurev-med-050124-025051","DOI":"10.1146\/annurev-med-050124-025051"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Shah P, King S, Trabanino S, et al. Ancestral variation in Lp(a): epidemiology, isoform diversity, and testing. Curr Atheroscler Rep 2025;27:117. https:\/\/doi.org\/10.1007\/s11883-025-01365-0; PMID: 41247582. DOI: 10.1007\/s11883-025-01365-0","DOI":"10.1007\/s11883-025-01365-0"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kronenberg F. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region. Clin Res Cardiol Suppl 2019;14(Suppl 1):5\u201312. https:\/\/doi.org\/10.1007\/s11789-019-00093-5; PMID: 30859385. DOI: 10.1007\/s11789-019-00093-5","DOI":"10.1007\/s11789-019-00093-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607\u201314. https:\/\/doi.org\/10.1007\/BF00201550; PMID: 2026424. DOI: 10.1007\/BF00201550","DOI":"10.1007\/BF00201550"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cinezan C, Magureanu DC, Hiceag ML, et al. Shared risk factors and molecular mechanisms between aortic stenosis and atherosclerosis: a rationale for therapeutic repositioning. Int J Mol Sci 2025;26:8163. https:\/\/doi.org\/10.3390\/ijms26178163; PMID: 40943088. DOI: 10.3390\/ijms26178163","DOI":"10.3390\/ijms26178163"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Khan MI, Zahir RS, Dominguez AC, Romeo FJ. Role of lipoprotein (A) in aortic valve stenosis: novel disease mechanisms and emerging pharmacotherapeutic approaches. Int J Cardiol Heart Vasc 2024;55:101543. https:\/\/doi.org\/10.1016\/j.ijcha.2024.101543; PMID: 39555492. DOI: 10.1016\/j.ijcha.2024.101543","DOI":"10.1016\/j.ijcha.2024.101543"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tsimikas S. Lp(a) and accelerated progression of aortic stenosis: a rationale for universal measurement and therapeutic targeting. JACC Asia 2024;4:761\u20133. https:\/\/doi.org\/10.1016\/j.jacasi.2024.08.008; PMID: 39553910. DOI: 10.1016\/j.jacasi.2024.08.008","DOI":"10.1016\/j.jacasi.2024.08.008"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63:470\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038; PMID: 24161338. DOI: 10.1016\/j.jacc.2013.09.038","DOI":"10.1016\/j.jacc.2013.09.038"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Arsenault BJ, Boekholdt SM, Dub\u00e9 MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014;7:304\u201310. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000400; PMID: 24704946. DOI: 10.1161\/CIRCGENETICS.113.000400","DOI":"10.1161\/CIRCGENETICS.113.000400"},{"key":"ref17","unstructured":"Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1109034; PMID: 23388002."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Khan K, Yu B, Kiwan C, et al. The role of Wnt\/\u03b2-catenin pathway mediators in aortic valve stenosis. Front Cell Dev Biol 2020;8:862. https:\/\/doi.org\/10.3389\/fcell.2020.00862; PMID: 33015048. DOI: 10.3389\/fcell.2020.00862","DOI":"10.3389\/fcell.2020.00862"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Di Costanzo A, Indolfi C, Franzone A, et al. Lp(a) in the pathogenesis of aortic stenosis and approach to therapy with antisense oligonucleotides or short interfering RNA. Int J Mol Sci 2023;24:14939. https:\/\/doi.org\/10.3390\/ijms241914939; PMID: 37834387. DOI: 10.3390\/ijms241914939","DOI":"10.3390\/ijms241914939"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pirillo A, Catapano AL. Lipoprotein (a): a new target for pharmacological research and an option for treatment. Eur J Intern Med 2025;139:106425. https:\/\/doi.org\/10.1016\/j.ejim.2025.07.021; PMID: 40713253. DOI: 10.1016\/j.ejim.2025.07.021","DOI":"10.1016\/j.ejim.2025.07.021"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023;374:107\u201320. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.012; PMID: 37188555. DOI: 10.1016\/j.atherosclerosis.2023.04.012","DOI":"10.1016\/j.atherosclerosis.2023.04.012"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Velho TR, Pereira RM, Fernandes F, et al. Bioprosthetic aortic valve degeneration: a review from a basic science perspective. Braz J Cardiovasc Surg 2022;37:239\u201350. https:\/\/doi.org\/10.21470\/1678-9741-2020-0635; PMID: 34673516. DOI: 10.21470\/1678-9741-2020-0635","DOI":"10.21470\/1678-9741-2020-0635"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Poniedzia\u0142ek B, Perek B, Proch A, et al. Mineral composition and ratios in aortic valves, serum, and epicardial fat among patients with aortic stenosis undergoing aortic valve replacement. Sci Rep 2025;15:1233. https:\/\/doi.org\/10.1038\/s41598-025-85141-9; PMID: 39775052. DOI: 10.1038\/s41598-025-85141-9","DOI":"10.1038\/s41598-025-85141-9"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Poniedzia\u0142ek B, Perek B, Proch A, et al. Rare earth elements in human calcified aortic valves and epicardial adipose tissue. J Clin Med 2025;14:2891. https:\/\/doi.org\/10.3390\/jcm14092891; PMID: 40363923. DOI: 10.3390\/jcm14092891","DOI":"10.3390\/jcm14092891"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Peletier M, Ali L, Dzobo K, et al. Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammation. Eur Heart J Open 2025;5:oeaf068. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf068; PMID: 40904944. DOI: 10.1093\/ehjopen\/oeaf068","DOI":"10.1093\/ehjopen\/oeaf068"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Obi MF, Sharma M, Ahmad S, et al. Lipoprotein(a)\u2019s role in atherosclerosis and aortic stenosis: a contemporary literature review. Cureus 2024;16:e62984. https:\/\/doi.org\/10.7759\/cureus.62984; PMID: 39044888. DOI: 10.7759\/cureus.62984","DOI":"10.7759\/cureus.62984"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995;76:928\u201332. https:\/\/doi.org\/10.1016\/S0002-9149(99)80263-X; PMID: 7484833. DOI: 10.1016\/S0002-9149(99)80263-X","DOI":"10.1016\/S0002-9149(99)80263-X"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Durr MRR, Burwash IG, Lau L, et al. Lipoprotein (a) distribution in aortic stenosis patients: are Lp(a) reducing agents the ultimate solution? JACC Adv 2025;4:101662. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101662; PMID: 40117697. DOI: 10.1016\/j.jacadv.2025.101662","DOI":"10.1016\/j.jacadv.2025.101662"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ao L, Noordam R, Jukema JW, et al. The interactions of lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank. Am J Prev Cardiol 2025;22:101008. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101008; PMID: 40510257. DOI: 10.1016\/j.ajpc.2025.101008","DOI":"10.1016\/j.ajpc.2025.101008"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ren Y, Deng Y. The predictive value of serum lipoprotein(a) level for new-onset aortic valve calcification in patients with coronary artery disease. BMC Cardiovasc Disord 2025;25:733. https:\/\/doi.org\/10.1186\/s12872-025-05196-4; PMID: 41074073. DOI: 10.1186\/s12872-025-05196-4","DOI":"10.1186\/s12872-025-05196-4"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wambua P, Wahinya M, Khan Z. The role of elevated lipoprotein(a) in aortic valve disease: a systematic review. Front Cardiovasc Med 2025;12:1610395. https:\/\/doi.org\/10.3389\/fcvm.2025.1610395; PMID: 41158733. DOI: 10.3389\/fcvm.2025.1610395","DOI":"10.3389\/fcvm.2025.1610395"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2016;36:1003\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306683; PMID: 26941019. DOI: 10.1161\/ATVBAHA.115.306683","DOI":"10.1161\/ATVBAHA.115.306683"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Brinck J, Littmann K, Hogling DE, et al. Elevated lipoprotein(a) and progression of aortic stenosis measured by Doppler echocardiography: a population-based cohort study. J Intern Med 2025;298:46\u20138. https:\/\/doi.org\/10.1111\/joim.20095; PMID: 40309928. DOI: 10.1111\/joim.20095","DOI":"10.1111\/joim.20095"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Arsenault BJ, Loganath K, Girard A, et al. Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis. JAMA Cardiol 2024;9:835\u201342. https:\/\/doi.org\/10.1001\/jamacardio.2024.1882; PMID: 39018080. DOI: 10.1001\/jamacardio.2024.1882","DOI":"10.1001\/jamacardio.2024.1882"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013;273:6\u201330. https:\/\/doi.org\/10.1111\/j.1365-2796.2012.02592.x; PMID: 22998429. DOI: 10.1111\/j.1365-2796.2012.02592.x","DOI":"10.1111\/j.1365-2796.2012.02592.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017;69:692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042; PMID: 28183512. DOI: 10.1016\/j.jacc.2016.11.042","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Chen HY, Dufresne L, Burr H, et al. Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records. JAMA Cardiol 2018;3:18\u201323. https:\/\/doi.org\/10.1001\/jamacardio.2017.4266; PMID: 29128868. DOI: 10.1001\/jamacardio.2017.4266","DOI":"10.1001\/jamacardio.2017.4266"},{"key":"ref38","unstructured":"Guertin J, Kaiser Y, Manikpurage H, et al. Sex-specific associations of genetically predicted circulating Lp(a) (lipoprotein(a)) and hepatic LPA gene expression levels with cardiovascular outcomes: Mendelian randomization and observational analyses. Circ Genom Precis Med 2021;14:e003271. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003271; PMID: 34279996."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Yu X, Fu Z, Yu M, Shi Y. Association of lipoprotein(a) and LPA gene with calcific aortic valve disease. Eur J Med Res 2025;30:787. https:\/\/doi.org\/10.1186\/s40001-025-03071-8; PMID: 40847316. DOI: 10.1186\/s40001-025-03071-8","DOI":"10.1186\/s40001-025-03071-8"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Luo D, Bj\u00f6rnson E, Wang X, et al. Distinct lipoprotein contributions to valvular heart disease: insights from genetic analysis. Int J Cardiol 2025;431:133218. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133218; PMID: 40157612. DOI: 10.1016\/j.ijcard.2025.133218","DOI":"10.1016\/j.ijcard.2025.133218"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Pantelidis P, Oikonomou E, Lampsas S, et al. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res 2023;119:1641\u201355. https:\/\/doi.org\/10.1093\/cvr\/cvad062; PMID: 37078819. DOI: 10.1093\/cvr\/cvad062","DOI":"10.1093\/cvr\/cvad062"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Kayikcioglu M. LDL apheresis and Lp (a) apheresis: a clinician\u2019s perspective. Curr Atheroscler Rep 2021;23:15. https:\/\/doi.org\/10.1007\/s11883-021-00911-w; PMID: 33594522. DOI: 10.1007\/s11883-021-00911-w","DOI":"10.1007\/s11883-021-00911-w"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Kay\u0131k\u00e7\u0131o\u011flu M, K\u0131smal\u0131 E, Can L, Payzin S. Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic. Turk Kardiyol Dern Ars 2014;42:599\u2013611 [in Turkish]. https:\/\/doi.org\/10.5543\/tkda.2014.09633; PMID: 25490294. DOI: 10.5543\/tkda.2014.09633","DOI":"10.5543\/tkda.2014.09633"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Tokgozoglu L, Kayikcioglu M. Familial hypercholesterolemia: global burden and approaches. Curr Cardiol Rep 2021;23:151. https:\/\/doi.org\/10.1007\/s11886-021-01565-5; PMID: 34480646. DOI: 10.1007\/s11886-021-01565-5","DOI":"10.1007\/s11886-021-01565-5"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kayikcioglu M, Tokgozoglu L, Dogan V, et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atherosclerosis 2018;277:341\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.012; PMID: 30270069. DOI: 10.1016\/j.atherosclerosis.2018.08.012","DOI":"10.1016\/j.atherosclerosis.2018.08.012"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"P\u00e9rez de Isla L, Watts GF, Alonso R, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J 2021;42:2201\u201311. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1066; PMID: 33437997. DOI: 10.1093\/eurheartj\/ehaa1066","DOI":"10.1093\/eurheartj\/ehaa1066"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Vuorio A, Watts GF, Kovanen PT. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis 2019;281:25\u201330. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.040; PMID: 30616181. DOI: 10.1016\/j.atherosclerosis.2018.11.040","DOI":"10.1016\/j.atherosclerosis.2018.11.040"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Sticchi E, Giusti B, Cordisco A, et al. Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study. Intern Emerg Med 2019;14:45\u201350. https:\/\/doi.org\/10.1007\/s11739-018-1925-8; PMID: 30099661. DOI: 10.1007\/s11739-018-1925-8","DOI":"10.1007\/s11739-018-1925-8"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Krzesi\u0144ska A, Nowak M, Mickiewicz A, et al. Lipoprotein(a) as a potential predictive factor for earlier aortic valve replacement in patients with bicuspid aortic valve. Biomedicines 2023;11:1823. https:\/\/doi.org\/10.3390\/biomedicines11071823; PMID: 37509461. DOI: 10.3390\/biomedicines11071823","DOI":"10.3390\/biomedicines11071823"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Ma GS, Wilkinson MJ, Reeves RR, et al. Lipoprotein(a) in patients undergoing transcatheter aortic valve replacement. Angiology 2019;70:332\u20136. https:\/\/doi.org\/10.1177\/0003319719826461; PMID: 30700108. DOI: 10.1177\/0003319719826461","DOI":"10.1177\/0003319719826461"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Loewenstein I, Lichtenstein D, Goldiner I, et al. Lipoprotein(a) levels in severe aortic stenosis referred for transcatheter aortic valve implantation compared to controls. JACC Adv 2024;3:101264. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101264; PMID: 39296820. DOI: 10.1016\/j.jacadv.2024.101264","DOI":"10.1016\/j.jacadv.2024.101264"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Shi W, Feng D, Hu X, et al. Lipoprotein(a) and high-sensitivity C-reactive protein compound the risk of hypoattenuating leaflet thickening after transcatheter aortic valve replacement. J Am Heart Assoc 2024;13:e035597. https:\/\/doi.org\/10.1161\/JAHA.124.035597; PMID: 39424417. DOI: 10.1161\/JAHA.124.035597","DOI":"10.1161\/JAHA.124.035597"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Hu X, Wang C, Feng D, et al. Association between lipoprotein(a) and long-term prognosis in patients receiving transcatheter aortic valve replacement. J Clin Lipidol 2025;19:544\u201353. https:\/\/doi.org\/10.1016\/j.jacl.2025.03.001; PMID: 40169331. DOI: 10.1016\/j.jacl.2025.03.001","DOI":"10.1016\/j.jacl.2025.03.001"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Sampath-Kumar R, Padilla E, Wilkinson M, et al. Impact of triglycerides and remnant particles on hemodynamic valve deterioration after transcatheter aortic valve replacement. JACC Adv 2025;4:102247. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102247; PMID: 41124988. DOI: 10.1016\/j.jacadv.2025.102247","DOI":"10.1016\/j.jacadv.2025.102247"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Bormann J, Rudolph F, Miller M, et al. The influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement. Clin Res Cardiol 2025;114:395\u2013404. https:\/\/doi.org\/10.1007\/s00392-024-02587-z; PMID: 39661146. DOI: 10.1007\/s00392-024-02587-z","DOI":"10.1007\/s00392-024-02587-z"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Farina JM, Chao CJ, Pereyra M, et al. Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration. Heart 2024;110:299\u2013305. https:\/\/doi.org\/10.1136\/heartjnl-2023-322987; PMID: 37643771. DOI: 10.1136\/heartjnl-2023-322987","DOI":"10.1136\/heartjnl-2023-322987"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Boute M, Salembier P, Pouleur AC, et al. Lipoprotein(a) and long-term structural valve degeneration of aortic bioprostheses. Eur Heart J Cardiovasc Imaging 2026;27:264\u201373. https:\/\/doi.org\/10.1093\/ehjci\/jeaf320; PMID: 41248067. DOI: 10.1093\/ehjci\/jeaf320","DOI":"10.1093\/ehjci\/jeaf320"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Botezatu SB, Tzolos E, Kaiser Y, et al. Serum lipoprotein(a) and bioprosthetic aortic valve degeneration. Eur Heart J Cardiovasc Imaging 2023;24:759\u201367. https:\/\/doi.org\/10.1093\/ehjci\/jeac274; PMID: 36662130. DOI: 10.1093\/ehjci\/jeac274","DOI":"10.1093\/ehjci\/jeac274"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Sorysz D, Dziewierz A, Gawlik K, et al. Temporal changes in biomarker levels and their association with the early degeneration stage of transcatheter aortic valves in 18F-fluorodeoxyglucose and 18F-sodium fluoride positron emission tomography studies. Postepy Kardiol Interwencyjnej 2024;20:329\u201337. https:\/\/doi.org\/10.5114\/aic.2024.142403; PMID: 39464587. DOI: 10.5114\/aic.2024.142403","DOI":"10.5114\/aic.2024.142403"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.900027; PMID: 20048204. DOI: 10.1161\/CIRCULATIONAHA.109.900027","DOI":"10.1161\/CIRCULATIONAHA.109.900027"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Rosseb\u00f8 AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343\u201356. https:\/\/doi.org\/10.1056\/NEJMoa0804602; PMID: 18765433. DOI: 10.1056\/NEJMoa0804602","DOI":"10.1056\/NEJMoa0804602"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Cowell SJ, Newby DE, Prescott RJ,, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389\u201397. https:\/\/doi.org\/10.1056\/NEJMoa043876; PMID: 15944423. DOI: 10.1056\/NEJMoa043876","DOI":"10.1056\/NEJMoa043876"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Yarahmadi P, Kabiri A, Forouzannia SM, Yousefifard M. Statins and mortality of patients after transcatheter aortic valve implantation: a systematic review and meta-analysis. Angiology 2023;74:611\u201323. https:\/\/doi.org\/10.1177\/00033197221124778; PMID: 36067358. DOI: 10.1177\/00033197221124778","DOI":"10.1177\/00033197221124778"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Baranowska J, T\u00f6rngren C, Nielsen SJ, et al. Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry. Eur Heart J Cardiovasc Pharmacother 2022;8:837\u201346. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac034; PMID: 35583235. DOI: 10.1093\/ehjcvp\/pvac034","DOI":"10.1093\/ehjcvp\/pvac034"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Bergmark BA, O\u2019Donoghue ML, Murphy SA, et al. An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial. JAMA Cardiol 2020;5:709\u201313. https:\/\/doi.org\/10.1001\/jamacardio.2020.0728; PMID: 32347887. DOI: 10.1001\/jamacardio.2020.0728","DOI":"10.1001\/jamacardio.2020.0728"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Langsted A, Nordestgaard BG, Benn M, et al. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. J Clin Endocrinol Metab 2016;101:3281\u20137. https:\/\/doi.org\/10.1210\/jc.2016-1206; PMID: 27218270. DOI: 10.1210\/jc.2016-1206","DOI":"10.1210\/jc.2016-1206"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ciofani JL, Han D, Rao K, et al. Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study. Eur Heart J Cardiovasc Pharmacother 2025;11:136\u201342. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae092; PMID: 39611306. DOI: 10.1093\/ehjcvp\/pvae092","DOI":"10.1093\/ehjcvp\/pvae092"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Surma S, Zembala MO, Okopie\u0144 B, Banach M. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation. Int J Cardiol Cardiovasc Risk Prev 2024;22:200297. https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200297; PMID: 38962113. DOI: 10.1016\/j.ijcrp.2024.200297","DOI":"10.1016\/j.ijcrp.2024.200297"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:59:34Z","timestamp":1788202774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":69,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.101","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"e47"}}